Advanced glycation end products in nondiabetic patients with coronary artery disease.
OBJECTIVE
To investigate whether advanced glycation end products (AGEs) participate in the development of coronary artery disease (CAD) in nondiabetic and diabetic subjects.


METHODS
Serum concentrations of AGEs were measured using a newly established enzyme-linked immunosorbent assay in 48 nondiabetic patients (normal glucose tolerance, n = 20; impaired glucose tolerance, n = 28) who received coronary angiography for the study of chest pain or suspected CAD. Insulin sensitivity was examined by the euglycemic-hyperinsulinemic glucose clamp technique and was estimated as the mean glucose infusion rate during the last 30 min of clamp time (M value).


RESULTS
Patients were classified into four groups based on the number of significantly stenosed vessels, defined as 0-, 1-, 2-, or 3-vessel disease. Serum concentrations of AGEs were significantly higher in nondiabetic subjects with CAD than in control subjects (2.42 +/- 0.65 vs. 1.96 +/- 0.40 mU/ml, P < 0.01) and significantly correlated with the number of significantly stenosed vessels (r = 0.678, P < 0.001). M values significantly inversely correlated with serum concentrations of AGEs (r = -0.490, P < 0.05). In multiple regression analysis, with the number of significantly stenosed vessels as the dependent variable, serum concentrations of AGEs, 2-h plasma glucose, and areas under the plasma glucose response curve were independently associated.


CONCLUSIONS
This pilot study indicates the relation between AGEs and the severity of CAD in nondiabetic patients. The measurement of serum AGE concentrations may be predictive of vascular damage.
Kanauchi
M
M
First Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, Japan.
Tsujimoto
N
N
Hashimoto
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D002637:Chest Pain; D017023:Coronary Angiography; D003327:Coronary Disease / Q000097:blood* / Q000145:classification / Q000503:physiopathology; D003404:Creatinine / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D012044:Regression Analysis
D015415:Biomarkers; D001786:Blood Glucose; D017127:Glycation End Products, Advanced; D007328:Insulin; D003404:Creatinine